VEEV has a higher market value than 95.48% of US stocks; more precisely, its current market capitalization is $44,468,151,050.
VEEV's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 902.76 -- higher than 96.27% of US-listed equities with positive expected earnings growth.
The price/operating cash flow metric for Veeva Systems Inc is higher than 96.07% of stocks in our set with a positive cash flow.
Stocks that are quantitatively similar to VEEV, based on their financial statements, market capitalization, and price volatility, are SEDG, NVCR, MPWR, QLYS, and RNG.
Veeva Systems provides cloud-based software solutions for the life sciences industry in North America, Europe, the Asia Pacific, and Latin America. The company was founded in 2007 and is based in Pleasanton, California.
According to a Markets and Markets report, the global market for healthcare cloud computing is expected to grow from $28.1 billion in 2020 to $64.7 billion by 2025 at a CAGR of 18.1%. Pleasanton, California-based Veeva (VEEV) recently reported its second-quarter results that continued to surpass all market expectations. Veeva's...
DBMR has added a new report titled Global eClinical Solutions Market with analysis provides the insights which bring marketplace clearly into the focus and thus help organizations make better decisions. The data and the information regarding the industry are taken from
Investment Thesis Veeva Systems (VEEV) is a leading vertical SaaS play focused on providing a core CRM product alongside other life science-focused software tools to a largely pharmaceutical and biotechnology company customer base. The stock has performed well, particularly vs. the S&P, as illustrated below: Data by YCharts The life...
Captain Alpha on Seeking Alpha | September 29, 2020
DUBLIN--(BUSINESS WIRE)--The "Global Risk-based Monitoring Software Market Analysis 2020" report has been added to ResearchAndMarkets.com's offering. The Global Risk-based Monitoring Software market is expected to reach $652.40 million by 2026 growing at a CAGR of 15.3% from 2019 to 2026. Risk-based monitoring (RBM) software is a clinical trial-monitoring method that fulfills regulatory necessities. It employs various tools, platforms and dashboards to identify signals, which indicate potential